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CD4+ T cells recognize and respond to peptide 
antigens in the context of MHCII. The nature of 
TCR–peptide MHC (pMHC) interactions de-
termines the stimulation threshold for positive 
and negative selection of T cells in the thymus, 
and it has also been shown to influence the lin-
eage  decisions  of  the  developing  cells  (Singer   
et al., 2008). For example, strong TCR signals 
have  been  proposed  to  guide  double-positive 
thymocytes toward the CD4 fate (Itano et al., 
1996). In peripheral T cells, the potency of TCR 
ligand can have a profound effect on the extent 
of activation; higher affinity TCR–pMHC in-
teractions generally lead to increased signaling 
downstream  of  the  TCR  and,  subsequently, 
more robust proliferation and cytokine produc-
tion (Davis et al., 1998; Germain and Stefanová, 
1999). In addition to influencing the magnitude 
of the T cell response, the potency and density   
of  pMHC  affinity  may  also  instruct  CD4+ 
helper differentiation (Constant et al., 1995;   
Hosken et al., 1995; Tao et al., 1997; Rogers and 
Croft, 1999).
Regulatory T cell (T reg cell) differentiation 
and function is also dependent on TCR stimula-
tion (Josefowicz and Rudensky, 2009; Shevach, 
2009). T reg cells are defined by their expression 
of the winged helix/forkhead transcription fac-
tor  forkhead  box  p3  (Foxp3)  and  have  been 
shown to suppress both pathological and healthy 
immune responses (Sakaguchi, 2004; Fontenot 
and Rudensky, 2005; Belkaid, 2007). Foxp3 is 
required for the development, maintenance, and 
suppressive function of these cells, as indicated 
by the multiorgan autoimmunity resulting from 
its loss of function in both mice and humans 
(Fontenot et al., 2003; Hori et al., 2003; Khattri 
et  al.,  2003;  Gavin  et  al.,  2007;  Zheng  and 
Rudensky, 2007). Foxp3+ T reg cells can be di-
vided into two categories based on their site of 
origin: thymic T reg cells and induced T reg 
cells, which leave the thymus as naive CD4+ 
Foxp3-negative T cells but then acquire Foxp3 
expression and suppressor function in the pe-
riphery (Curotto de Lafaille and Lafaille, 2009).
The requirement for TCR stimulation in 
the thymic development of T reg cell is illus-
trated by the failure of TCR transgenic T cells 
to express Foxp3 in the absence of endogenous 
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T cell receptor (TCR) ligation is required for the extrathymic differentiation of forkhead box 
p3+ (Foxp3+) regulatory T cells. Several lines of evidence indicate that weak TCR stimulation 
favors induction of Foxp3 in the periphery; however, it remains to be determined how TCR 
ligand potency influences this process. We characterized the density and affinity of TCR ligand 
favorable for Foxp3 induction and found that a low dose of a strong agonist resulted in  
maximal induction of Foxp3 in vivo. Initial Foxp3 induction by weak agonist peptide could be 
enhanced by disruption of TCR–peptide major histocompatibility complex (pMHC) interactions 
or alteration of peptide dose. However, time course experiments revealed that Foxp3-positive 
cells induced by weak agonist stimulation are deleted, along with their Foxp3-negative coun-
terparts, whereas Foxp3-positive cells induced by low doses of the strong agonist persist. Our 
results suggest that, together, pMHC ligand potency, density, and duration of TCR interactions 
define a cumulative quantity of TCR stimulation that determines initial peripheral Foxp3 
induction. However, in the persistence of induced Foxp3+ T cells, TCR ligand potency and 
density are noninterchangeable factors that influence the route to peripheral tolerance.
© 2010 Gottschalk et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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peptides in our system. However, Foxp3+ cells induced by the 
weak agonist peptides did not persist compared with those 
generated by the higher affinity ligand. Our data suggest that it 
is the cumulative level of TCR stimulation that determines 
initial induction of Foxp3 in the periphery but that TCR li-
gand density and potency are noninterchangeable factors in the 
persistence of the induced Foxp3+ population.
RESULTS
There is an inverse relationship between TCR/pMHC affinity  
and optimal peptide concentration for Foxp3 induction in vitro
To explore the impact of TCR/pMHC affinity on peripheral 
Foxp3 induction we used 5C.C7 T cells, which recognize a 
peptide from moth cytochrome c (MCC; 88–103) in the con-
text of the MHCII molecule I-Ek (Davis et al., 1998). The 
5C.C7 TCR is ideal for addressing this question because, in 
addition to the natural ligand MCC, a wide variety of related 
peptide ligands have been characterized for their TCR binding 
properties and in vitro activating potencies (Reay et al., 1994; 
Rabinowitz et al., 1996; Wilson et al., 1999; Li et al., 2004; 
Krogsgaard et al., 2005). In addition to MCC, we assessed 
Foxp3 induction by the weak agonist peptide 102S (Reay   
et al., 1994; Rabinowitz et al., 1996) and the superagonist K5 
(Krogsgaard et al., 2003, 2005; Li et al., 2004), both of which 
TCR rearrangement, unless their cognate antigen is present 
(Olivares-Villagómez et al., 1998; Itoh et al., 1999; Jordan   
et al., 2001; Apostolou et al., 2002; Kawahata et al., 2002).   
The selection of T reg cells upon encounter of transgenically 
expressed neo-autoantigens suggests that TCR specificity for 
self could play a role in T reg cell development, which is con-
sistent with a study demonstrating that T reg cell TCRs are 
more  self-reactive  than  their  non–T  reg  cell  counterparts 
(Hsieh et al., 2004). Thymic T reg cell selection may be associ-
ated with relatively strong TCR stimulation because thymo-
cytes expressing a TCR more weakly stimulated by its antigen 
were  not  selected  to  be  T  reg  cells  (Jordan  et  al.,  2001).   
Another study implicated superior survival of Foxp3+ thymo-
cytes in contributing to the increased frequency of T reg cells 
observed in TCR transgenic systems where the cognate anti-
gen was expressed (van Santen et al., 2004). Differences in the 
strength of TCR–pMHC interactions could determine T reg 
cell selection versus deletion of self-reactive thymocytes. That 
TCRs preferentially used by T reg cells in wild-type mice are 
also present in the repertoires of Foxp3-deficient mice is con-
sistent with the notion that these TCR–self-pMHC interac-
tions fall between the avidity ranges resulting in positive and 
negative selection (Hsieh et al., 2006).
TCR specificity has also been implicated in Foxp3 expres-
sion by induced T reg cells (Lathrop et al., 2008). Stimulation 
of adoptively transferred TCR transgenic T cells demonstrated 
that peripheral Foxp3 induction is associated with subop-
timal  activation  and  inversely  correlates  with  proliferation 
(Kretschmer et al., 2005). Consistent with these in vivo find-
ings, more recent in vitro studies have suggested a mechanism 
by which extensive TCR stimulation is detrimental for the 
generation of induced T reg cells; constitutive or prolonged 
signaling  through  the  Akt–PI3K–mTor  pathway,  which  is 
downstream of the TCR, antagonizes the induction of Foxp3 
(Haxhinasto et al., 2008; Sauer et al., 2008). Another possible 
explanation for the negative impact of robust TCR signaling 
on induced T reg cell generation is cell cycle–dependent main-
tenance of a silenced state of the Foxp3 locus (Josefowicz et al., 
2009). Collectively, these data suggest that weak TCR stimu-
lation is favorable for the peripheral induction of Foxp3 
(Kretschmer et al., 2005; Haxhinasto et al., 2008; Sauer et al., 
2008; Josefowicz et al., 2009).
Although it is clear that the level of TCR stimulation influ-
ences Foxp3 induction, several factors impact the cumulative 
TCR stimulation a cell receives, such as TCR ligand density 
and the affinity and duration of TCR–pMHC interactions.   
In this study, we sought to define the TCR ligand characteristics 
ideal for in vitro and in vivo induction of Foxp3 using TCR 
transgenic T cells recognizing a panel of peptide ligands with 
varying affinities for the TCR. Given the current assumption 
that weaker TCR stimulation favors peripheral Foxp3 induc-
tion, we were surprised to find that a low-affinity agonist was 
greatly diminished in its ability to induce a persistent popula-
tion of Foxp3-expressing cells in vivo. Modulating the dura-
tion of TCR–pMHC interactions and the density of pMHC 
resulted in efficient initial Foxp3 induction by weak agonist 
Figure 1.  There is an inverse relationship between TCR/pMHC  
affinity and the optimal peptide concentration for Foxp3 induction  
in vitro. (A) EC50 values for the experiment shown were determined as the 
peptide concentration resulting in 50% of maximal proliferation. LN cells 
from 5C.C7 TCR transgenic RAG2/ mice were stimulated with irradiated 
splenocytes and the indicated peptide for 60 h. 3H-methyl-thymidine was 
used to assess proliferation. (B and C) 5C.C7 RAG2/ LN cells were cultured 
with irradiated splenocytes in the presence of IL-2 and the indicated pep-
tide for 4 d before flow cytometry analysis of the frequency (B) or number 
(C) of Foxp3+ cells. (C) Percentage of maximum cell number is shown, with 
Foxp3+ 5C.C7 represented as a solid line and Foxp3 cells as a dashed line. 
In A and B, error bars show mean ± SD, with n = 3 or n = 2 wells, respec-
tively. Data are representative of at least three independent experiments.JEM VOL. 207, August 2, 2010 
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response  to  two  peptides  differing  in   
their EC50 values (Turner et al., 2009), 
and with  in  vivo  data  indicating  that 
Foxp3 induction is favored by condi-
tions suboptimal for proliferation of re-
sponding cells (Kretschmer et al., 2005).
The addition of exogenous TGF-, 
a factor known to facilitate TCR- 
dependent  Foxp3  induction  (Chen   
et al., 2003; Selvaraj and Geiger, 2007), 
widened the range of TCR stimulation over which Foxp3 
induction occurred in vitro (Fig. S1). Furthermore, the su-
peragonist K5 resulted in the most Foxp3+ cells, peaking at 
concentrations of peptide higher than favorable for Foxp3 
induction in the absence of exogenous TGF-. Thus, in 
terms of Foxp3 induction, TGF- reduces the sensitivity to 
strong stimulation through the TCR. This is consistent with 
the requirement of TGF- and other negative regulators for 
Foxp3 induction in systems relying on relatively strong TCR 
stimulation (Chen et al., 2003; Zheng et al., 2006; Selvaraj 
and Geiger, 2007). Our in vitro data suggest that the combi-
nation of ligand density and affinity determine an optimal 
range of TCR stimulation conducive for expression of Foxp3. 
Sensitivity to variations in these parameters is decreased in the 
presence of exogenous TGF-.
The weak agonist 102S yields diminished frequency  
and number of induced Foxp3+ 5C.C7 T cells in vivo
To dissect the effects of antigen density and affinity on Foxp3 
induction in vivo, we opted for a single intravenous dose of 
peptide, which has previously been shown to tolerize a mono-
clonal population of antigen-specific T cells (Thorstenson and 
Khoruts, 2001). Low doses of MCC peptide were able to   
induce  Foxp3  expression  in  adoptively  transferred  5C.C7   
T cells (Fig. 2 A). Over a 100-fold titration of peptide, we found 
0.1 µg MCC to be optimal for peripheral Foxp3 induction, 
contain mutations in TCR contact residues that result in a 
shorter or longer half-life of 5C.C7 TCR–pMHC interac-
tions, respectively (Corse et al., 2010; Huppa et al., 2010).   
All of the peptides used in our study bind to MHC with compara-
ble affinity (Krogsgaard et al., 2003), which is essential to sepa-
rate the influences of TCR ligand potency versus density of 
pMHC ligand upon T cell responses. To confirm the rank   
order of the peptides in our experimental setting, we stimulated 
5C.C7 T cells with irradiated splenocytes and the indicated ti-
tration of peptide (Fig. 1 A). As expected, at equivalent doses 
of peptide 102S induced less 5C.C7 proliferation and K5 more 
proliferation, relative to the natural ligand MCC. This differ-
ence in in vitro potency is apparent in the higher and lower 
EC50 values for 102S and K5, respectively (Fig. 1 A).
To assess the ability of the various ligands to induce Foxp3 
in vitro, 5C.C7 T cells were stimulated in the presence of exog-
enous IL-2 and a titration of peptide. Interestingly, to reach peak 
in vitro Foxp3 induction for each ligand, the peptide concentra-
tion had to be adjusted to compensate for affinity. Relative to 
MCC, a higher concentration of 102S and a lower concentra-
tion of K5 was required (Fig. 1 B). For all three peptides, the 
optimal concentration for in vitro Foxp3 induction is below the 
concentration of peptide required for expansion of the Foxp3-
negative compartment within the same cultures (Fig. 1 C). 
These results are consistent with a recently published study, 
comparing in vitro Foxp3 induction and proliferation in   
Figure 2.  A single low dose of intra-
venous MCC peptide results in efficient 
peripheral induction of Foxp3. B10.A mice 
containing 106 naive adoptively transferred 
5C.C7 RAG2/ CD45.1 T cells were injected 
intravenously with the indicated dose of MCC 
peptide. CD4+CD45.1+ cells were assessed for 
expression of Foxp3 (A and B) and CD44 (in 
the Foxp3 population; C). (D) A time course 
was performed to assess Foxp3 expression 
and CFSE dilution of adoptively transferred 
5C.C7 at each indicated day after peptide 
injection. The frequency of Foxp3+ cells, as  
a percentage of total 5C.C7, is shown on the 
plots. Error bars show mean ± SD of two mice 
per group, and data are representative of at 
least three independent experiments. Dot 
plots in A are gated on CD4+ cells, whereas all 
other plots and histograms are gated on 
CD4+CD45.1+, unless otherwise indicated.1704 TCR ligand density and affinity in Foxp3 induction | Gottschalk et al.
Foxp3 induction (Kretschmer et al., 2005; Haxhinasto et al., 
2008; Sauer et al., 2008; Josefowicz et al., 2009), we were sur-
prised to find that the weak agonist 102S appeared diminished 
in its ability to induce expression of Foxp3. Although intrave-
nous administration of 102S peptide did result in some Foxp3 
expression, the percentage of 5C.C7 expressing Foxp3 was 
fourfold less than that observed with the optimal dose of MCC 
8 d after peptide injection (Fig. 3, A and C). Furthermore, 
normalization  to  remove  the  effect  of  the  Foxp3  5C.C7   
T cells from the calculation revealed a drastically smaller number 
Foxp3+ 5C.C7 in the 102S-treated mice, compared with both 
high-affinity ligands (Fig. 3 B). We detected even less Foxp3 
induction upon further increase of the dose to 100 µg (Fig. 3, 
A and B). This indicates that optimal Foxp3 induction by the 
102S ligand cannot be accomplished by further increasing the 
concentration of peptide. This could not be attributed to de-
creased in vivo stability of 102S compared with MCC, as both 
peptides appeared to be cleared at a comparable rate (Fig. S3).
Disruption of TCR–pMHC interactions in vivo can inhibit 
proliferation while enhancing Foxp3 induction
To better understand the diminished ability of 102S to in-
duce Foxp3 in vivo, we examined proliferation of Foxp3+ 
and Foxp3 5C.C7 T cells in response to the various peptides 
and doses. In contrast to stimulation that favored Foxp3 in-
duction (0.1 µg MCC; Fig. 2D), 10 µg 102S resulted in pro-
liferation by the majority of 5C.C7 T cells (Fig. 4 A, left). 
We  hypothesized  that  decreasing  the  level  of  cumulative 
TCR stimulation in conditions where the majority of 102S-
stimulated cells were dividing would favor Foxp3 induction. 
We sought to do this by manipulating the duration of TCR 
stimulation. It has previously been demonstrated using two-
photon imaging that T cell–APC interactions can be dis-
rupted  in  vivo  by  injection  of  an  MHCII  antibody  after 
peptide injection (Celli et al., 2007). Using this approach, we 
interfered with TCR–pMHC interactions at various times 
after peptide administration by injecting a monoclonal anti-
body to the MHCII molecule I-Ek (Fig. 4).
Strikingly, injection of anti-MHCII between 6 to 16 h 
after  peptide  administration  resulted  in  enhanced  Foxp3   
induction by the weak agonist 102S (Fig. 4, A and B), which 
was assayed 6 d after peptide injection. This was true both in 
terms of the frequency and number of Foxp3+ 5C.C7 T cells 
(Fig.  4,  B  and  C).  Disrupting  TCR–pMHC  interactions 
during the hours in which formation and persistence of sta-
ble T cell–APC contacts dictate subsequent effector function 
(Hugues et al., 2004; Miller et al., 2004; Celli et al., 2007; 
but not 36 h after peptide injection; Fig. 4, A and B), low-
ered the level of cumulative stimulation, as assessed by CFSE 
dilution, and changed the response of the 5C.C7 T cells. This 
resulted in an increased frequency of Foxp3-expressing cells, 
whereas proliferation of the entire 5C.C7 population was 
reduced (Fig. 4, D and E). In contrast, administration of anti- 
MHCII subsequent to stimulation with the optimal dose of 
MCC results in fewer Foxp3+ 5C.C7 T cells (Fig. S4),   
suggesting  that  the  reduced  level  of  TCR  stimulation   
both in terms of the percentage of 5C.C7 expressing Foxp3 
and the number of 5C.C7 Foxp3+ cells (Fig. 2 B). This dose 
was below the threshold of activation required for complete 
CD44 up-regulation of the 5C.C7 Foxp3 cells (Fig. 2 C) 
and resulted in only partial CFSE dilution (Fig. 2 D). This 
suggests that in our system, induction of Foxp3 expression is 
coincident with a weaker TCR signal (in terms of a lower 
peptide dose). A time course after injection of the optimal 
dose showed that although Foxp3 can be detected in some 
5C.C7 T cells as early as 2.5 d after immunization, peak accu-
mulation of Foxp3+ 5C.C7 T cells occurs between 4 and 10 d 
after immunization (Fig. 2 D). 5C.C7 T cells induced to ex-
press Foxp3 under our experimental conditions express high 
levels of CD25 and CTLA-4 and display phenotypic charac-
teristics common to T reg cells (Fig. S2). Consistent with pre-
vious studies (Kretschmer et al., 2005; Josefowicz et al., 2009), 
these Foxp3+ 5C.C7 T cells had undergone only a few cell 
divisions, with the majority remaining undivided at early time 
points (Fig. 2 D, days 2.5 and 4; and Fig. S2 D).
We addressed the influence of TCR/pMHC affinity on   
in vivo Foxp3 induction by comparing varying doses of the 
weak agonist 102S and the superagonist K5 with MCC 8 d   
after peptide injection (Fig. 3). All three peptides, including 
the weak agonist 102S, are able to stimulate canonical in vivo   
T cell responses, including proliferation, cytokine production, 
and  memory,  upon  subcutaneous  immunization  with  LPS 
(Corse et al., 2010). In response to intravenous peptide injec-
tion, we found K5 to induce comparable numbers of Foxp3+ 
5C.C7 T cells as MCC at the same low doses of peptide   
(Fig. 3 B). Given results that low levels of TCR stimulation favor 
Figure 3.  The weak agonist 102S results in a diminished frequency 
and number of induced Foxp3+ 5C.C7 T cells in vivo. B10.A recipients 
received 5C.C7 RAG2/ CD45.1 T cells and were subsequently injected 
with the indicated dose of 102S, MCC, or K5 peptide. After 8 d, LN cells 
were assessed for the percentage (A) and number, as normalized to  
the endogenous CD4+CD45.2+ population (B), of 5C.C7 T cells expressing 
Foxp3. Error bars show mean ± SD of two mice per group and data are 
representative of at least three independent experiments. (C) Below the 
graphs are representative CD4+CD45.1+ gated dot plots, with the percent-
age of Foxp3+ cells shown on the plot.JEM VOL. 207, August 2, 2010 
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Foxp3+ 5C.C7 induced by injection of weak agonist peptide 
do not persist
Considering that disruption of TCR–pMHC interactions 
in vivo leads to reduced proliferation coincident with Foxp3 
induction, we examined whether there was a dose of 102S 
that would stimulate cell division, which is comparable to 
low doses of MCC. In this more refined in vivo titration, 
we also included the peptide 102N, another weak agonist 
that induces comparable or slightly less in vitro IL-2 pro-
duction  and  conjugate  formation  than  102S  (Egen  and   
Allison,  2002).  A  titration  of  MCC,  102S,  and  102N   
in vivo showed that dose could compensate for pMHC po-
tency in stimulating comparable amounts of proliferation. 
There was a dose of each peptide that resulted in a similar 
intermediate level of CFSE dilution 5 d after peptide injec-
tion (0.3 µg MCC, 3 µg 102S, and 10 µg 102N; Fig. 5,   
A and B [boxed data points]; and Fig. S6 A, full titration). 
This readout suggests that all three peptides are capable of 
achieving a similar level of TCR stimulation. Consistent 
with this, 2 d after stimulation with these doses of MCC 
and 102S we detected equivalent levels of ki67 expression 
and Akt phosphorylation, which represents the degree of 
activity of Akt kinase and mTORC2 complex (Fig. 5 E). 
This  comparable  amount  of  Akt  phosphorylation  is  of   
under these conditions falls below the range conducive for   
Foxp3 induction.
Slightly reduced proliferation and increased Foxp3 ex-
pression upon blockade was seen in mice injected with 10 µg 
MCC, with the effect being less drastic than for 102S (Fig. 4, 
D and E). This may be explained by the observation that 
102S-stimulated cells express the proliferation antigen ki67 
with a temporal delay, compared with MCC at the same dose 
of peptide, indicating that the cells responding to stimulation 
with the lower affinity ligand may require more time to enter 
the cell cycle (Fig. S5 A). At 10 µg, the majority of MCC-
stimulated cells are ki67+ by 24 h, whereas ki67 expression is 
not detected in most 102S-stimulated cells until after 48 h 
(Fig. S5 A). Thus, disruption of TCR–pMHC interactions 
after 102S injection resulted in an increased portion of 5C.C7 
T cells below the threshold of stimulation required for ki67 
expression, whereas cells stimulated with 10 µg MCC are all 
ki67+ by 48 h, regardless of antibody treatment (Fig. S5 B). 
This is consistent with the modest effect of MHC blockade 
on the proliferative capacity and Foxp3 expression of 5C.C7 
T cells responding to MCC (Fig. 4, D and E) but does not 
exclude the possibility that there are doses of MCC at which 
Foxp3 induction could be more efficiently enhanced by 
MHC blockade.
Figure 4.  Disruption of TCR–pMHC interactions in vivo can inhibit proliferation while enhancing Foxp3 induction. B10.A recipients were adop-
tively transferred with naive CFSE-labeled CD45.1+ 5C.C7 T cells and subsequently injected with the indicated peptide followed by intravenous anti-MHCII 
at the indicated times. CD45.1+ LN cells were analyzed 6 d after peptide injection. (A and B) Antibody to MHCII was injected at varying time points after 
injection with 10 µg 102S, and the frequency of Foxp3+ 5C.C7 T cells was assessed. Representative dot plots (A) are shown beside data pooled from two 
independent experiments. Each point represents one mouse and horizontal bars indicate the mean (B). (C) The influence of anti-MHCII injection on the 
number of Foxp3+ 5C.C7 T cells was addressed by normalizing to the endogenous CD4+CD45.2+ population. n = 2 with SD. (D and E) Anti-MHCII was in-
jected between 8 and 10 h after injection of either MCC or 102S, as indicated. 5C.C7 CFSE dilution and Foxp3 expression was assessed (D). Percentage of 
5C.C7 expressing Foxp3 versus the proliferative capacity of the total 5C.C7 population are analyzed in a scatter plot. Data are pooled from at least three 
independent experiments, each data point representing one mouse (E). Dot plots are gated on CD4+CD45.1+ cells, and the percentages that are positive 
for Foxp3 are shown. All data are representative of at least three independent experiments.1706 TCR ligand density and affinity in Foxp3 induction | Gottschalk et al.
As expected, the dose for each peptide that triggered   
partial division of the responding 5C.C7 population was also 
the peak of Foxp3 induction, based on the percentage of 
Foxp3+ 5C.C7 T cells (0.3 µg MCC, 3 µg 102S, and 10 µg 
102N; Fig. 5, B and C). Although the peak of Foxp3 induc-
tion by 102S peptide in this more refined titration (3 µg) 
produced slightly more Foxp3 induction than 10 µg, both 
doses still resulted in diminished numbers of Foxp3+ 5C.C7 
T cells compared with MCC. The numbers of 102S-induced 
Foxp3+ 5C.C7 T cells were lower at day 8 (Fig. 3) than at 
day 5 (Fig. 5 D). Thus, to gain more insight into the fate of 
cells stimulated by these strong and weak agonists, we quan-
titated the number of Foxp3+ and Foxp3 5C.C7 T cells 
over time (Fig. 6 and Fig. S7).
We found that intravenous injection with either MCC or 
102S resulted in a dose-dependent expansion and sharp con-
traction, just after the peak of the response (Fig. S7, A and B). 
As a control, we immunized with the same dose of peptide 
subcutaneously, at the base of tail with LPS, which generates 
a more typical effector response and does not result in such 
drastic cell loss (Fig. S7 A). The contraction of 5C.C7 T cells 
responding to intravenous peptide injection is consistent with 
studies reporting deletion of T cells stimulated by intravenous 
peptide as a mechanism of tolerance (Kearney et al., 1994; 
Liblau et al., 1996). When comparing the doses of MCC, 
102S, and 102N that result in a comparable level of prolifera-
tion, we observed a similar decline in number of 5C.C7   
T cells in both the LNs and the spleen (Fig. S7, C and D). 
This apparent deletion was coincident with the presence of   
a fraction of 5C.C7 T cells positive for active caspases, which 
was not present in recipients that did not receive peptide in-
jection and is consistent with cell death in response to toler-
izing antigen administration (Fig. S7 E).
The two weak agonist peptides assessed in our system   
are able to induce a substantial frequency of Foxp3+ 5C.C7   
T cells if the right dose of peptide is administered. At early 
time points, all three peptides induce a comparable percentage 
of Foxp3+ 5C.C7 (Fig. 6, days 2.5 and 5). However, Foxp3+ 
5C.C7 induced by the low-affinity ligands disappear quickly 
after the peak of the response, within the same time frame as 
the Foxp3 compartment, whereas a low dose of MCC re-
sults in increased frequencies and numbers of Foxp3+ 5C.C7 
throughout the course of the experiment (Fig. 6). Consider-
ing the loss of the Foxp3 5C.C7 T cells in all of these condi-
tions (Fig. 6 A), it is the persistence of the Foxp3+ 5C.C7 
population after low-dose MCC stimulation that is specific, 
rather than the deletion of either 5C.C7 compartment after 
stimulation with weak ligand. We do not attribute the differ-
ence in Foxp3+ 5C.C7 persistence to an inability of 5C.C7   
T cells responding to 102S peptide to produce IL-2 (Fig. S8).
Our measurements of the degree of proliferation and initial 
Foxp3 induction suggest that increasing the dose of 102S re-
sults in the same quantity of stimulation as received by MCC-
stimulated cells. However, time course experiments revealed 
that a low dose of the strong agonist peptide, but not a high 
dose of weak agonist, was able to induce a persistent population 
particular interest considering recent studies reporting that 
the Akt–mTor pathway, which is essential for T cell activa-
tion and proliferation, may antagonize peripheral Foxp3 
induction (Haxhinasto et al., 2008; Sauer et al., 2008). The 
level of phospho-Akt correlated with ki67 expression, re-
gardless of stimulating peptide (Fig. 5 F).
Figure 5.  In vivo, peptide dose compensates for potency to reach 
comparable levels of proliferation and Akt phosphorylation, but not 
numbers, of Foxp3-expressing 5C.C7 T cells. Naive 5C.C7 RAG2/ 
CD45.1 T cells were adoptively transferred and stimulated in vivo by intra-
venous injection of the indicated peptide and dose. All dot plots and histo-
grams are gated on CD4+CD45.1+ LN cells. (A) Day-5 representative dot 
plots for each peptide at the doses yielding comparable frequencies of 
divided cells and peak of Foxp3 induction: 0.3 µg MCC, 3 µg 102S, and  
10 µg 102N. The percentage of divided (B), percentage of Foxp3+ (C), and 
number of Foxp3+ 5C.C7 T cells (D) 5 d after injection of the indicated pep-
tide and dose are shown with SD. n = 2. The dashed rectangle in B indi-
cates the optimal peptide doses. (E and F) 2 d after injecting doses of MCC 
and 102S that yield comparable CFSE dilution (0.3 µg MCC and 3 µg 102S), 
ki67 expression and Akt phosphorylation in total 5C.C7 T cells were mea-
sured by flow cytometry. Bar graphs in E show data pooled from three 
independent experiments with SD. As a control, Akt phosphorylation was 
compared with the maximum resulting from immunization at the base of 
tail with MCC and LPS, which results in a substantial portion of pAkt+ 5C.
C7 T cells. Histograms in F separate CD4+CD45.1+ cells by ki67 expression, 
adjacent to linear regression analysis of the percentage of 5C.C7 express-
ing ki67 versus the phospho-Akt MFI for the total 5C.C7 population, for 
individual samples (best fit line shown: R2 = 0.647; P = 0.016). All data are 
representative of at least three independent experiments.JEM VOL. 207, August 2, 2010 
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density and the strength of TCR–pMHC interactions on the 
peripheral induction of Foxp3 in vivo.
Upon  comparing  ligands  of  varying  affinities  across  an   
in vitro peptide titration, we found that there was a limited range 
of TCR stimulation over which Foxp3 induction occurred. 
Relative to the natural ligand MCC, peak Foxp3 induction by 
the superagonist K5 occurred at lower concentrations of pep-
tide, whereas the peak induction by the weak agonist 102S oc-
curred at higher concentrations. All three ligands were able to 
induce a comparable magnitude of in vitro conversion of 5C.
C7 T cells, so long as peptide concentration was altered to 
compensate for a higher or lower affinity ligand. For each pep-
tide,  the  TCR  stimulation  range  favoring  conversion  was   
below the concentration of peptide required for expansion of 
the nonconverted cells. The addition of exogenous TGF- 
widened the range of TCR stimulation over which conversion 
occurred, which allowed for Foxp3 induction at concentra-
tions of peptide that were otherwise too high. This is consis-
tent  with  previously  published  reports  demonstrating  the 
requirement for TGF- and other negative regulators of T cell 
activation in scenarios where T cells are receiving high levels 
of TCR stimulation (Chen et al., 2003; Zheng et al., 2006; 
Selvaraj and Geiger, 2007).
When MCC, K5, and 102S were titrated in vivo, we did 
not observe the same simple relationship between ligand affin-
ity and optimal Foxp3 induction dose seen in vitro. The super-
agonist peptide K5, which peaked at concentrations of peptide 
100-fold lower than MCC in vitro, was comparable to MCC 
in vivo, resulting in efficient conversion of 5C.C7 T cells at the 
same low dose. Strikingly, stimulation with the weak agonist 
102S resulted in drastically reduced numbers of Foxp3+ 5C.C7 
T cells 8 d after peptide injection, compared with either of the 
strong ligands. This was surprising given the studies reporting 
of Foxp3+ T cells. Thus, there are two phases that must be 
considered. In the first phase, antigen dose can compensate for 
potency to achieve the optimal quantity of TCR stimulation 
for initial Foxp3 induction, whereas in the second phase, high 
doses of peptide are detrimental to the persistence of the stimu-
lated 5C.C7 T cells, including the induced Foxp3+ T cells in 
the case of the weak agonist peptide. This highlights limitations 
of comparing in vivo and in vitro systems, the latter of which 
do not address the issue of persistence.
DISCUSSION
Foxp3+ T reg cell suppression of self-reactive effector T cells is 
critical for the prevention of autoimmunity (Sakaguchi, 2004). 
Peripheral induction of Foxp3 in mature CD4+ T cells may be 
an important mechanism of maintaining this self-tolerance. 
The partial overlap of TCR repertoires of induced T reg cells 
and thymic T reg cells indicates that peripheral Foxp3 induc-
tion could potentially offer a second chance for self-reactive 
cells that escape thymic selection to enter the T reg cell lineage 
(Lathrop et al., 2008). Alternatively, cells could convert into   
T reg cells in response to non–self-antigens presented in toler-
izing conditions (Curotto de Lafaille and Lafaille, 2009). Under-
standing the conditions optimal for peripheral Foxp3 induction 
in vivo could provide insight into how this process may be 
manipulated in a therapeutic setting.
Several studies altering antigen dose and degree of Akt 
and/or mTor activity have shown that efficient Foxp3 induc-
tion occurs in conditions suboptimal for activation (Kretschmer 
et al., 2005; Haxhinasto et al., 2008; Sauer et al., 2008), sug-
gesting that a weaker TCR stimulation favors peripheral con-
version. It was less clear how defined TCR/pMHC binding 
parameters, such as affinity and off rate, influence this process. 
In this study, we address the cumulative influence of antigen 
Figure 6.  Foxp3+ 5C.C7 induced by in-
jection of weak agonist peptide do not 
persist, compared with the high-affinity 
ligand MCC. After adoptive transfer of 5C.C7 
RAG2/ CD45.1 T cells, recipient mice were 
injected with varying doses of the indicated 
peptides, which have been previously deter-
mined to give equivalent CFSE dilution and 
peak Foxp3 induction (0.3 µg MCC, 3 µg 102S, 
and 10 µg 102N), and then sacrificed at the 
indicated time points after peptide injection. 
(A) The percentage of Foxp3+ and numbers of 
Foxp3+ and Foxp3 5C.C7 in LN were assessed 
at each time point. Error bars show SD of two 
mice per group. Representative dot plots 
gated on CD4+CD45.1+ cells are shown in B, 
with the percentage of Foxp3-positive 5C.C7 
shown on the plot. Data are representative of 
at least three independent experiments.1708 TCR ligand density and affinity in Foxp3 induction | Gottschalk et al.
Our system suggests that the range of TCR stimulation favor-
ing this process is very narrow, as the dose response for all 
three peptides is very steep. Based on our in vitro data, where 
the addition of TGF- allowed for Foxp3 induction in re-
sponse to higher concentrations of peptide, we would expect 
that a particular cytokine environment could also widen the 
range of TCR stimulation over which Foxp3 induction could 
occur in vivo. In addition, our results suggest that it may be 
conceivable to expand the range of antigenic conditions over 
which Foxp3 induction can occur in a therapeutic setting 
through manipulation of the duration of TCR–pMHC inter-
actions. Disrupting T cell–APC interactions allowed us to de-
crease the cumulative TCR stimulation, resulting in Foxp3 
induction when ligand density would otherwise be unfavor-
able. In doing so, it may be possible to alter the frequency of 
antigen-specific T reg cell, which could skew a potentially 
pathogenic T cell response toward tolerance.
Despite finding doses of 102S and 102N that yielded sim-
ilar proliferation and initial Foxp3 induction compared with 
optimal doses of MCC, these weak agonists still generated 
diminished numbers of Foxp3+ 5C.C7 T cells at longer times 
after peptide injection. Time course experiments revealed 
that at the doses of each peptide yielding optimal initial Foxp3 
induction, injection of weak agonist peptides resulted in sim-
ilar deletion of both the Foxp3 negative and positive popula-
tions, whereas stimulation with MCC resulted in specific 
persistence of the induced Foxp3+ population of 5C.C7   
T cells. Thus, there are two phases influencing the numbers 
of Foxp3+ 5C.C7 observed after in vivo stimulation. During 
initial induction of Foxp3, antigen dose could compensate 
for potency to achieve the optimal quantity of TCR stimula-
tion, whereas in the second phase, maintenance versus dele-
tion of this population appeared to be determined by unique 
stimulation criteria. This highlights the importance of study-
ing in vivo systems, as persistence is not addressed in short 
term  in  vitro  assays.  Low-potency  ligands  are  efficient  at 
achieving the weak TCR signals favoring Foxp3 induction 
both in vitro and in vivo. However, our data demonstrate 
that these interactions do not necessarily induce a persistent 
population of Foxp3+ T cells in vivo.
Our findings demonstrate that ligand potency and den-
sity are  noninterchangeable  factors.  Increasing  the  dose  of   
low-potency ligand appeared to achieve a similar level of   
cumulative TCR stimulation (comparable proliferation, Akt 
phosphorylation, and Foxp3 induction at early time points) but 
failed to generate persistent Foxp3+ 5C.C7, compared with the 
strong agonist MCC. Therefore it is not simply a matter of 
getting the same quantity of TCR stimulation; there are quali-
tative differences that must be considered. This difference in 
cell fate suggests that there may be mechanisms allowing   
T cells to discriminate between signals comings from a few 
strong  TCR–pMHC  interactions,  versus  many  complexes 
with weaker interactions. One can imagine the triggering of 
survival  signals  specifically  downstream  of  a  strong  TCR–
pMHC interaction, as opposed to proapoptotic signals which 
are induced by the triggering of many separate TCRs. There is 
that  weaker  TCR  stimulation  favors  Foxp3  induction 
(Kretschmer et al., 2005; Haxhinasto et al., 2008; Sauer et al., 
2008). Thus, we went on to modulate multiple parameters   
influencing the level of TCR stimulation received by 102S-
stimulated cells to optimize Foxp3 induction, and subsequently   
assessed the frequencies and numbers of Foxp3+ 5C.C7 T cells 
induced by the strong and weak agonists over time.
Upon assessing proliferation of cells responding to 10 µg 
102S, the dose where we had observed a detectable frequency 
of Foxp3+ 5C.C7, it appeared that induction of Foxp3 by 
5C.C7 T cells responding to 10 µg 102S was accompanied by 
proliferation more robust than that in conditions that are   
optimal for Foxp3 induction (i.e., 0.1 µg MCC peptide).   
The idea that such a strong stimulation would be detrimental to 
Foxp3 induction is consistent with studies demonstrating that 
Akt activity can antagonize expression of Foxp3 (Haxhinasto 
et al., 2008; Sauer et al., 2008). In addition, proliferation may 
oppose Foxp3 induction by cell cycle–dependent recruitment 
of maintenance DNA methyltransferase, which results in a   
silenced state of the Foxp3 locus (Josefowicz et al., 2009).
Considering these findings, we sought to decrease the cu-
mulative TCR stimulation in response to this high density of 
102S pMHC complexes by injecting antibodies to MHCII 6–
16 h after injection of peptide. During this time period, T cell–
APC contacts form and persist, and antibodies to MHCII have 
been shown to result in disruption of T cell–APC interactions 
(Hugues et al., 2004; Miller et al., 2004; Celli et al., 2007). By 
blocking TCR–pMHC interactions, we were able to both de-
crease  the  frequency  of  102S-stimulated  cells  entering  cell   
cycle and greatly lower their overall proliferative capacity, which 
correlated with increased initial induction of Foxp3. These re-
sults highlight the influence of pMHC potency, density, and 
duration of interactions with TCR on the overall quantity of 
TCR stimulation that a cell receives and, thus, its decision to 
divide or express Foxp3.
Together, our data are in agreement with the idea that 
weak TCR stimulation that is suboptimal for proliferation 
favors initial Foxp3 induction. Indeed, a refined titration of 
peptides in vivo revealed that both MCC and the two weak 
ligands 102S and 102N could produce this favorable quantity 
of TCR stimulation if the dose was adjusted to compensate 
for ligand strength. At these doses, which span nearly two or-
ders of magnitude between MCC and 102N, stimulation by 
all three peptides resulted in equivalent Foxp3 induction, 
based on the frequency of Foxp3+ 5C.C7 at early time points. 
In conditions favoring optimal Foxp3 induction, there was 
no difference in the ability of strong and weak ligands to trig-
ger Akt phosphorylation, which simply correlated with ki67 
expression, regardless of stimulating peptide.
Considering only the initial induction of Foxp3, our data 
varying ligand dose, potency, and duration of TCR–pMHC 
interactions in vivo would suggest that perhaps it is simply the 
quantity of TCR stimulation that is important. This would be 
consistent with a model in which all of these factors contrib-
ute to a cumulative signal, which determines T cell responses 
(Rosette et al., 2001; Rachmilewitz and Lanzavecchia, 2002). JEM VOL. 207, August 2, 2010 
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effects of maintaining T reg cells that recognize ubiquitous 
self-ligands, such as bystander suppression (Masteller et al., 
2005; Tang and Bluestone, 2008).
In  summary,  initial  in  vivo  Foxp3  induction  can  be 
achieved  by  optimizing  the  quantity  of  cumulative  TCR 
stimulation, which can be thought of as a sum of the factors 
of ligand potency, density, and duration of TCR–pMHC in-
teractions. However, TCR ligand potency and density are 
clearly noninterchangeable in determining the persistence of 
the cells induced to express Foxp3. These findings provide 
important insight into how affinity and prevalence of antigen 
may determine the route to peripheral tolerance.
MATERIALS AND METHODS
Mice. 5C.C7 TCR transgenic RAG2/ mice (Taconic) were bred to B10.
A CD45.1 (provided by W. Paul via the National Institute of Allergy and 
Infectious Diseases contract facility at Taconic) to generate 5C.C7 RAG2/ 
CD45.1 mice, which were used as donor mice in adoptive transfer experi-
ments. Male B10.A mice (Taconic) were used as adoptive transfer recipients 
at between 6 and 9 wk of age. All mice were maintained in microisolator 
cages, and treated in accordance with the regulations of the National Insti-
tutes of Health and the American Association of Laboratory Animal Care. 
Experiments in this study were approved by the Memorial Sloan-Kettering 
Cancer Center Institutional Animal Care and Use Committee.
In vitro T cell activation and Foxp3 induction. Cells were cultured in 
a 37°C humidified chamber with 5% CO2 in complete RPMI1640 (supple-
mented with 10% FCS, 2 µM glutamine, 100 U/ml penicillin and strepto-
mycin, and 2 µM 2-mercaptoethanol). Single cell suspensions were prepared 
from  LNs  harvested  from  5C.C7  RAG2/  mice  (routinely  >90% 
Vll+V3+ by flow cytometry) and stimulated in duplicate or triplicate,   
as indicated, in 96-well round bottom plates. In T cell proliferation assays,   
3 × 104 5C.C7 cells were stimulated with 2 × 105 irradiated splenocytes and 
the indicated peptides for 60 h. 1 µCi/well 3H-methyl-thymidine was used 
to monitor T cell proliferation. Cells were harvested onto glass-fiber filters   
using a Tomtec harvester, and filters were counted using a MicroBeta scintilla-
tion counter (PerkinElmer). For in vitro T reg cell conversion assays,   
105 5C.C7 T cells were cultured with 4 × 105 irradiated splenocytes that had 
been depleted of T cells using CD90.2 microbeads (Miltenyi Biotec), the in-
dicated peptide, and 100 U/ml of recombinant human IL-2 (PeproTech), 
with or without human TGF-1 (PeproTech). Cells were cultured for   
90–96 h before cells were stained for flow cytometry analysis. In some cul-
tures the absolute number of cells was determined using an automated cell 
counter (Guava Technologies Inc.).
Peptides.  Peptides  were  synthesized  and  HPLC  purified  (≥95%)  by 
Biosynthesis, Inc.
Flow cytometry and antibodies. Flow cytometry was done on an LSRII 
(BD). Antibodies to surface markers were obtained from BD, eBioscience, or 
BioLegend. Foxp3 was detected using antibodies (eBioscience) and fixation/
permeabilization reagents. For detection of phosph-Akt (Ser473), we used 
an Alexa Fluor 647–conjugated antibody (Cell Signaling Technology; DE9), 
after immediate fixation with 2% paraformaldehyde and subsequent permea-
bilization with cold methanol. CTLA-4 and ki67 antibodies (BD) were de-
tected after fixation and permeabilization as required for Foxp3 or phospho- 
Akt analysis, depending on the experiment.
In vivo Foxp3 induction. Between 5 × 105 and 1 × 106 5C.C7 RAG2/ 
CD45.1 T cells were transferred into B10.A recipients by tail vein injection. 
Mice were subsequently immunized intravenously the same or next day with 
0.03–100 µg of peptide diluted in PBS. When disruption of T cell–APC in-
teractions was desired, 500 µg of monoclonal antibody to the mouse MHC 
precedent for cell-intrinsic mechanisms of ligand discrimina-
tion via negative signaling feedback loops, which is proposed 
to be important in the discrimination of self- and foreign li-
gands (Stefanová et al., 2003). In addition, it has been sug-
gested that the density of antigen may influence TCR signal 
inhibition, based on an in vivo model comparing tolerance in 
response to high and low levels of self-antigen (Singh and 
Schwartz, 2003).
Although is probable that cell-intrinsic mechanisms could 
be in place to aid in discrimination between high-potency 
versus high-density ligands, it is also possible that cell-extrinsic 
factors play a role in this process. This seems especially im-
portant  considering  that  the  maturation  state  of  APCs  is 
known to play an important role in T cell fate under toleriz-
ing conditions. Low levels of costimulation favor Foxp3 in-
duction (Benson et al., 2007), anergy, and deletion (Hawiger 
et al., 2001). Both dose and potency of peptide ligand have 
been reported to influence the kinetics and type of effector   
T cell–APC contact formation (Bousso and Robey, 2003; 
Skokos et al., 2007; Henrickson et al., 2008). Thus, it is pos-
sible that low doses of MCC and high doses of 102S achieve 
comparable cumulative TCR stimulation, but in the context 
of different types of T cell–APC interactions. For example, 
very low concentrations of peptide may only result in short 
interactions, which, given a potent ligand, may be sufficient 
to provide the minimal stimulation required for Foxp3 in-
duction. In this scenario, more stable T cell–APC interac-
tions resulting from higher concentrations of peptide could 
play a role in the subsequent deletion of these cells. Transient 
TCR–pMHC interactions upon low-dose injection of pep-
tide could explain the similarity in levels of Foxp3 induction 
by MCC and K5 we observed, as the increased potency of 
the high-affinity superagonist may be minimized in the ab-
sence of more stable conjugate formation.
We propose that a low density of a high-affinity TCR li-
gand is optimal to achieve the quantity and quality of stimu-
lation required to induce a persistent population of Foxp3+  
T cells in vivo. In fact, considering that the Foxp3 5C.C7   
T cells are deleted in these same conditions, and that injec-
tion of high doses of either MCC or 102S results in compa-
rable loss of 5C.C7 T cells, specificity is most apparent in the 
survival of the Foxp3+ 5C.C7 in response to small amounts 
of strong ligand. Deletion and Foxp3 induction are two pro-
posed mechanisms of peripheral tolerance. However, how 
the strength and density of TCR ligand steers a self-reactive 
T cell between these fates is understudied. TCR repertoire 
analysis has suggested that T reg cells may recognize self- 
antigens with low avidity (Hsieh et al., 2004). We suggest 
that low concentrations of specific self-pMHC complexes 
could contribute to peripheral Foxp3 induction in response 
to self-antigens, even if the TCR–pMHC interaction is of a 
high affinity. In the case of more abundantly expressed self-
pMHC complexes, our data suggest that deletion of the cog-
nate T cells is a more likely mechanism of tolerance, regardless 
of the strength of the ligand and extent of Foxp3 induction. 
It is interesting to speculate that there could be detrimental 1710 TCR ligand density and affinity in Foxp3 induction | Gottschalk et al.
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